Pin-Nan Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pin-Nan Cheng has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
Yen-Cheng Chiu
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
12 shared publications- Ming-Lung Yu
Center of Excellence for Metabolic Associated Fatty Liver Disease National Sun Yat‐sen University Kaohsiung Taiwan
11 shared publications - Ting-Tsung Chang
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
11 shared publications Hung-Chih Chiu
10 shared publicationsKuo-Chih Tseng
Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, School of Medicine, Tzu Chi University, Hualien, Taiwan
10 shared publications- Chun-Jen Liu
Division of Gastroenterology and Hepatology, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
9 shared publications
Latest Publications
- 2 November 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (11)
Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors
Data on hepatitis B virus reactivation (HBVr) during tyrosine kinase inhibitor (TKI) therapy remain limited. We prospectively enrolled patients with chronic or resolved HBV receiving TKIs for lung cancer or chronic myeloid leukemia at one Taiwanese center (January 2023–March 2025). HBV DNA and liver enzymes were monitored 12‐weekly and HBsAg 24‐weekly. HBVr was defined by AASLD criteria, with APASL and EASL definitions applied secondarily. Among 79 patients (20 HBsAg‐positive, 59 resolved HBV), none received antiviral prophylaxis. Median follow‐up was 42 weeks (IQR, 19–65). HBVr occurred in 7 (8.9%; 95% CI, 4.4%–17.2%): 5 HBsAg‐positive (25.0%; 95% CI, 11.2%–46.9%), and 2 with resolved HBV (3.4%; 95% CI, 0.9%–11.5%). APASL and EASL definitions yielded 30.0% and 35.0% in HBsAg‐positive patients, with no additional events in resolved HBV. No HBVr‐associated hepatitis flare meeting the study definition was observed, although transient flares between assessments could not be excluded and deterioration in one fatal case was attributed clinically to sepsis. Median HBVr detection time was 19 weeks (IQR, 14–30). Week‐48 Kaplan–Meier HBVr incidence was 37.5% (95% CI, 17.0%–69.5%) in HBsAg‐positive and 5.6% (95% CI, 1.4%–21.2%) in resolved HBV (log‐rank p < 0.001); Aalen–Johansen estimates were 28.3% (95% CI, 9.5%–50.9%) and 4.3% (95% CI, 0.8%–13.2%), respectively. In exploratory Firth‐corrected regression, HBsAg positivity was associated with HBVr (HR, 6.95; 95% CI, 1.60–40.19), while osimertinib exposure was not. HBVr was common among HBsAg‐positive patients and less common but not negligible among those with resolved HBV receiving TKIs.
- 2 November 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (11)
Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors
Data on hepatitis B virus reactivation (HBVr) during tyrosine kinase inhibitor (TKI) therapy remain limited. We prospectively enrolled patients with chronic or resolved HBV receiving TKIs for lung cancer or chronic myeloid leukemia at one Taiwanese center (January 2023–March 2025). HBV DNA and liver enzymes were monitored 12‐weekly and HBsAg 24‐weekly. HBVr was defined by AASLD criteria, with APASL and EASL definitions applied secondarily. Among 79 patients (20 HBsAg‐positive, 59 resolved HBV), none received antiviral prophylaxis. Median follow‐up was 42 weeks (IQR, 19–65). HBVr occurred in 7 (8.9%; 95% CI, 4.4%–17.2%): 5 HBsAg‐positive (25.0%; 95% CI, 11.2%–46.9%), and 2 with resolved HBV (3.4%; 95% CI, 0.9%–11.5%). APASL and EASL definitions yielded 30.0% and 35.0% in HBsAg‐positive patients, with no additional events in resolved HBV. No HBVr‐associated hepatitis flare meeting the study definition was observed, although transient flares between assessments could not be excluded and deterioration in one fatal case was attributed clinically to sepsis. Median HBVr detection time was 19 weeks (IQR, 14–30). Week‐48 Kaplan–Meier HBVr incidence was 37.5% (95% CI, 17.0%–69.5%) in HBsAg‐positive and 5.6% (95% CI, 1.4%–21.2%) in resolved HBV (log‐rank p < 0.001); Aalen–Johansen estimates were 28.3% (95% CI, 9.5%–50.9%) and 4.3% (95% CI, 0.8%–13.2%), respectively. In exploratory Firth‐corrected regression, HBsAg positivity was associated with HBVr (HR, 6.95; 95% CI, 1.60–40.19), while osimertinib exposure was not. HBVr was common among HBsAg‐positive patients and less common but not negligible among those with resolved HBV receiving TKIs.
- 22 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70926
Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and obesity share common pathogenesis and are increasingly relevant in clinical care. This joint statement addresses the need for comprehensive guidance in Taiwan for MASLD patients with obesity. The Gastroenterological Society of Taiwan, the Taiwan Association for the Study of the Liver, and the Taiwan Medical Association for the Study of Obesity conducted an evidence‐based review, integrating epidemiological data, clinical trial outcomes, and expert consensus to develop position statements covering diagnosis, disease burden, pathogenesis, surveillance, and therapeutic strategies. MASLD prevalence in Taiwanese adults is 30%–45%, reaching 60%–70% in individuals with obesity, with similar high prevalence in children and adolescents. Obesity accelerates hepatic and extrahepatic disease progression, including cirrhosis, hepatocellular carcinoma, and cardiovascular complications. Lifestyle interventions, glucagon‐like peptide‐1 receptor agonists, resmetirom, and bariatric surgery demonstrate efficacy in improving hepatic and metabolic outcomes. Risk stratification using noninvasive tools such as Fibrosis‐4 and vibration‐controlled transient elastography effectively guides referral and management. A multidisciplinary, precision‐based approach, integrating lifestyle modification, pharmacotherapy, surgical options, and risk stratification, is essential for effective MASLD management in patients with obesity, while research into artificial intelligence‐driven biomarkers, gut microbiota modulation, and genetic factors represents future directions.
- 22 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70926
Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and obesity share common pathogenesis and are increasingly relevant in clinical care. This joint statement addresses the need for comprehensive guidance in Taiwan for MASLD patients with obesity. The Gastroenterological Society of Taiwan, the Taiwan Association for the Study of the Liver, and the Taiwan Medical Association for the Study of Obesity conducted an evidence‐based review, integrating epidemiological data, clinical trial outcomes, and expert consensus to develop position statements covering diagnosis, disease burden, pathogenesis, surveillance, and therapeutic strategies. MASLD prevalence in Taiwanese adults is 30%–45%, reaching 60%–70% in individuals with obesity, with similar high prevalence in children and adolescents. Obesity accelerates hepatic and extrahepatic disease progression, including cirrhosis, hepatocellular carcinoma, and cardiovascular complications. Lifestyle interventions, glucagon‐like peptide‐1 receptor agonists, resmetirom, and bariatric surgery demonstrate efficacy in improving hepatic and metabolic outcomes. Risk stratification using noninvasive tools such as Fibrosis‐4 and vibration‐controlled transient elastography effectively guides referral and management. A multidisciplinary, precision‐based approach, integrating lifestyle modification, pharmacotherapy, surgical options, and risk stratification, is essential for effective MASLD management in patients with obesity, while research into artificial intelligence‐driven biomarkers, gut microbiota modulation, and genetic factors represents future directions.
- 19 November 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 232, 116109
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
- 19 November 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 232, 116109
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
- Open Access
- 5 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1) , 101616
Enhanced nuclear localization of small heterodimer partner in metabolic dysfunction-associated steatohepatitis
- 5 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1) , 101616
Open AccessEnhanced nuclear localization of small heterodimer partner in metabolic dysfunction-associated steatohepatitis
- Open Access
- 9 June 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (5) , 566-573
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)
- 9 June 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (5) , 566-573
Open AccessLong-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)
- 11 March 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (13) , 2637-2638
Refining Risk Estimates of Colorectal Cancer in Steatotic Liver Disease: Insights on Methodological Challenges
- 11 March 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (13) , 2637-2638
Refining Risk Estimates of Colorectal Cancer in Steatotic Liver Disease: Insights on Methodological Challenges
- Open Access
- 28 February 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 223-231
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
- 28 February 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 223-231
Open AccessPosttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
- Open Access
- 6 February 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (4) , 406-414
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C
- 6 February 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (4) , 406-414
Open AccessHigh-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C